Vyvanse Adds 14-Hour Duration Data As Shire's ADHD Drugs Face Off With Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
Duration of use data will help to strengthen Vyvanse's position in the fast-growing adult segment, Shire says.
You may also be interested in...
Business News, In Brief
Celgene ups 2010 guidance; Revlimid drives growth: Celgene increased its guidance for the year, with total revenues expected to grow about 25 percent year-over-year to $3.3 billion-$3.4 billion, up from a previous range of $3.2 billion-$3.3 billion, execs said during a first quarter earnings call April 29. The biopharma also expects sales of the cancer product Revlimid (lenalidomide) to grow 30 percent year-over-year, ranging from $2.2 billion-$2.3 billion. Leerink Swann analysts seemed encouraged by Revlimid's growth potential. "We believe the presentations of the CALGB-100104 and IFM-05-02 trials on maintenance in the post-stem cell transplant setting" at the ASCO annual scientific meeting "could be important catalysts for adoption of Revlimid in this setting," they said in a same day note. "A previous MEDACorp survey following the release of the CALGB data in late December 2009 showed that 89 percent (33 of 37) of hematologists/oncologists surveyed indicated they would increase their use of Revlimid in this setting as a result of the trial," they added. For the quarter, Revlimid brought in global sales of $530.5 million, up 46 percent
Shire Settles Adderall XR Patent Case With Impax, But Remains At Impasse With Barr
If a generic amphetamine extended-release launches before 2010, Impax will sell Shire’s authorized generic.
Shire Citizen Petition Seeks to Block Adderall XR Generics
The timing of Shire's petition likely was influenced by the forthcoming end of the 30-month stay on Barr's ANDA.